Der er rapporteret tilfælde med retroperitoneal fibrose, pulmonære infiltrater, pleuraleksudat, pleural fortykkelse, pericarditis og kardial valvulopati hos nogle patienter, som behandles med dopaminerge ergolinderivater.
Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents.